Loading…
The Inducible Expression of Dominant-Negative Epidermal Growth Factor Receptor-CD533 Results in Radiosensitization of Human Mammary Carcinoma Cells
Ionizing radiation activates the epidermal growth factor receptor (EGFR) and downstream signaling involving the cytoprotective mitogen-activated protein kinase (MAPK) pathway. In our effort to investigate the role of EGFR in cellular responses to radiation, we generated mammary carcinoma cell clones...
Saved in:
Published in: | Clinical cancer research 1999-02, Vol.5 (2), p.405-411 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Ionizing radiation activates the epidermal growth factor receptor (EGFR) and downstream signaling involving the cytoprotective
mitogen-activated protein kinase (MAPK) pathway. In our effort to investigate the role of EGFR in cellular responses to radiation,
we generated mammary carcinoma cell clones, MCF-TR5-EGFR-CD533 and MDA-TR15-EGFR-CD533, that inducibly express EGFR-CD533,
a truncated EGFR mutant lacking mitogenic and transformation activity. EGFR-CD533 expression inhibits radiation- and EGF-induced
EGFR autophosphorylation and MAPK activation and, therefore, functions as a dominant-negative mutant without blocking the
expression of EGFR or erbB-2, another member of the erbB receptor Tyr kinase family. Expression of EGFR-CD533 only minimally
inhibited cell growth and did not alter radiosensitivity to single radiation exposures. However, repeated 2 Gy radiation exposures
of cells, under conditions of EGFR-CD533 expression, essentially abolished their ability for subsequent cell growth. These
results identify the inhibition of EGFR function through genetic manipulation as a potential therapeutic maneuver. The concept
of such an intervention would be the radiosensitization of cells by counteracting a radiation-induced cytoprotective proliferation
response. |
---|---|
ISSN: | 1078-0432 1557-3265 |